A notable aspect of the present findings is that amplification of the CYP19A1 gene (aromatase), within the context of TCGA data cohort, was not correlated with breast cancer death [16], even though aromatase is the rate-limiting enzyme in estrogen biosynthesis. This evidence concerns the gene CYP19A1 and breast carcinoma.